Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
UMEC 62.5 mcg vs tiotropium 18 mcg in COPD
2014-000884-42Phase 3Completed
- Sponsor
- GSK
- Start
- Jun 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of umeclidinium in chronic obstructive pulmonary disease (COPD) (2 arms), sponsored by GSK. Primary endpoint: Clinic visit trough FEV1 on Treatment Day 85. Started Jun 2014; status: completed.
02
Drugs
umeclidinium
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on 2014-000884-42.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-000884-42.